. SMC2 therapeutic target validation. a) Relative mRNA levels after SMC2 silencing for PANC-1 pancreatic cancer cell line (siSMC2). Fold change was represented with respect to mRNA levels obtained from non-specific siRNA sequence treated cells (siControl); b) SMC2 and beta-tubulin proteins detected by western blot after SMC2 silencing compared to siControl treated cells (C); c) Cell viability assay for PANC-1 adherent cells after treatment with siSMC2 and siControl; d) Relative cell number percentage for PANC-1 cells growing in non-adherent conditions treated with siSMC2 and siControl.
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